secwatch.observer — SEC 8-K summary
======================================

Issuer:     Candel Therapeutics, Inc. (CADL)
CIK:        0001841387
Form:       8-K
Filed at:   2024-11-14T23:59:59+00:00
Accession:  0000950170-24-126759
Event type: earnings
Sentiment:  negative
Materiality: 0.70
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Candel Therapeutics Q3 net loss $10.6M, cash $16.6M; key prostate cancer data on track for Q4 2024
--------------------------------------------------------------------------------

- Net loss of $10.6M in Q3 2024 vs $8.4M in Q3 2023; includes $1.9M other expense from warrant liability.
- Cash and cash equivalents $16.6M as of Sept 30, 2024, down from $35.4M at Dec 31, 2023; expects funding to end of Q1 2025.
- On track for phase 2b and phase 3 topline data for CAN-2409 in prostate cancer in Q4 2024.
- CAN-3110 received FDA orphan drug designation for recurrent high-grade glioma; preclinical melanoma data presented.
- R&D expenses $5.4M (down $0.4M YoY); G&A expenses $3.3M (up $0.3M YoY).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024126759/0000950170-24-126759-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1841387/000095017024126759/cadl-20241114.htm
  HTML page:      https://secwatch.observer/filing/0000950170-24-126759

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer